Erasca Inc. (NASDAQ: ERAS) Stock Information | RedChip

Erasca Inc. (NASDAQ: ERAS)


$2.5850
+0.1050 ( +3.82% ) 855.7K

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Market Data


Open


$2.5850

Previous close


$2.4800

Volume


855.7K

Market cap


$703.99M

Day range


$2.4600 - $2.5990

52 week range


$1.6400 - $3.4500

SEC Filings


Form Type Description Pages Date
8-k 8K-related 12 Nov 12, 2024
10-q Quarterly Reports 72 Nov 12, 2024
8-k 8K-related 11 Oct 24, 2024
8-k 8K-related 12 Aug 12, 2024
10-q Quarterly Reports 76 Aug 12, 2024
8-k 8K-related 11 Jun 24, 2024
8-k 8K-related 11 Jun 24, 2024
4 Insider transactions 1 Jun 21, 2024
4 Insider transactions 1 Jun 21, 2024
4 Insider transactions 1 Jun 21, 2024

Latest News